Abstract 2355P
Background
Carcinoembryonic antigen (CEA; CEACAM5) is a cell surface glycoprotein which constitutes an attractive therapeutic target and serum CEA is used for cancer monitoring. CEA is overexpressed in various cancers, but the reported prevalence data vary considerably for many tumor types.
Methods
To comprehensively determine CEA expression in normal and neoplastic tissues, a tissue microarray containing 15,413 samples from 120 different tumor types and subtypes as well as 76 different normal tissue types were analyzed by immunohistochemistry.
Results
CEA positivity occurred in 65 of 120 tumor categories including 49 entities with at least one strongly positive case. CEA positivity was most common in colorectal carcinomas (98.7%), other gastrointestinal adenocarcinomas (61.1%-80.3%), medullary carcinomas of the thyroid (96.3%), pulmonary adenocarcinoma (73.7%), mucinous carcinomas of the ovary (79.8%) and the breast (43.2%), squamous cell carcinomas of various sites (30.2%-69.1%), and small cell carcinomas of the lung (64.3%), the urinary bladder (38.9%), and the prostate (50.0%). High CEA expression was linked to high grade (p<0.0001) and invasive growth (p<0.0001) in urothelial carcinoma. Reduced CEA expression was associated with mismatch repair deficiency (p<0.0001) but not with pT and pN stage in colorectal cancer.
Conclusions
In summary, CEA is abundantly expressed in a broad range of epithelial neoplasms. Our data thus identify various tumor entities where CEA positive cancers might best benefit from CEA serum monitoring and anti-CEA therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Sauter: Other, Personal, Other, The CEA (MSVA-465R) antibody were provided by MS Validated Antibodies GmbH, owned by a family member of Guido Sauter, Director of the Institute: MSVA. All other authors have declared no conflicts of interest.
Resources from the same session
2357P - TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation
Presenter: Sumin Lim
Session: Poster session 16
2358P - Assessing the efficacy of robot-assisted total gastrectomy for advanced proximal gastric cancer: Results from a three-year clinical trial
Presenter: Zhi-Yu Liu
Session: Poster session 16